Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734584 | 0.93 | TP53 (0.34) | ALDH1A1MAPK8 | |
| SCHEMBL29454705 | 0.93 | TP53 (0.34) | ALDH1A1MAPK8 | |
| SCHEMBL22734603 | 0.91 | ALDH1A1 (0.32) | ALDH1A1MAPT | |
| SCHEMBL29440686 | 0.91 | ALDH1A1 (0.32) | ALDH1A1MAPT | |
| SCHEMBL22734618 | 0.90 | MAPT (0.34) | ALDH1A1MAPK8MAPT | |
| SCHEMBL29440683 | 0.90 | MAPT (0.34) | ALDH1A1MAPK8MAPT | |
| SCHEMBL22734557 | 0.84 | MAPT (0.33) | MAPT | |
| SCHEMBL29440700 | 0.84 | MAPT (0.33) | MAPT | |
| SCHEMBL22734525 | 0.83 | MEN1 (0.35) | ALDH1A1MAPT | |
| SCHEMBL22734588 | 0.83 | MAPT (0.35) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | claimed |
| CN-114206860-B | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | claimed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | claimed |
| EP-4255911-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2023-10-11 | — | — | EP | claimed |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-04 | — | — | US | claimed |
| WO-2022117783-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-06-09 | — | — | WO | claimed |
| EP-3980414-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | Elanco Tiergesundheit AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-114206860-A | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | claimed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | claimed |
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | disclosed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | disclosed |
| WO-2024213752-A1 | LONG-TERM PREVENTION AND/OR TREATMENT OF A DISEASE BY SLO-1 INHIBITORS | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-10-17 | — | — | WO | disclosed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4255911-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2022117783-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | ALDH1A1 1017/4885MAPK8 4435/4885MAPT 4735/4885 |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, TNNI3 | ALDH1A1 611/4885MAPK8 4107/4885MAPT 4805/4885 |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | TBXA2R, PIGS, CYCS | ALDH1A1 1017/4885MAPK8 4435/4885MAPT 4735/4885 |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | CYCS, FABP3, TNNI3 | ALDH1A1 891/4885MAPK8 3937/4885MAPT 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.